MGMT and central nervous system cancer: After adjusting for the five clinicopathological factors (age, grade, IDH status, 1p/19q status and O6-methylguanine-DNA methyltransferase (MGMT) status), ANXA2 expression remained an independent prognostic factor for glioma patients (Fig. 3).